787 related articles for article (PubMed ID: 29449049)
21. An update on the management of urinary tract infections in the era of antimicrobial resistance.
Bader MS; Loeb M; Brooks AA
Postgrad Med; 2017 Mar; 129(2):242-258. PubMed ID: 27712137
[TBL] [Abstract][Full Text] [Related]
22. Aminoglycoside therapy for childhood urinary tract infection due to extended-spectrum β-lactamase-producing Escherichia coli or Klebsiella pneumoniae.
Han SB; Lee SC; Lee SY; Jeong DC; Kang JH
BMC Infect Dis; 2015 Oct; 15():414. PubMed ID: 26464143
[TBL] [Abstract][Full Text] [Related]
23. Retrospective assessment of antimicrobial stewardship initiative in outpatient use of ertapenem for uncomplicated extended spectrum beta lactamase Enterobacteriaceae urinary tract infections.
Wong CP; Delate T; Hudson E; Nguyen JK; Yang SJ; Abraham M
BMC Infect Dis; 2021 Aug; 21(1):823. PubMed ID: 34399680
[TBL] [Abstract][Full Text] [Related]
24. Risk factors for urinary tract infection caused by Enterobacteriaceae with extended-spectrum beta-lactamase resistance in patients admitted to internal medicine departments.
Vardi M; Kochavi T; Denekamp Y; Bitterman H
Isr Med Assoc J; 2012 Feb; 14(2):115-8. PubMed ID: 22693794
[TBL] [Abstract][Full Text] [Related]
25. Extended-Spectrum Beta-Lactamase-Producing Enterobacteriaceae-Related Urinary Tract Infection in Kidney Transplant Recipients: Risk Factors, Treatment, and Long-Term Outcome.
Brakemeier S; Taxeidi SI; Zukunft B; Schmidt D; Gaedeke J; Dürr M; Hansen S; Budde K
Transplant Proc; 2017 Oct; 49(8):1757-1765. PubMed ID: 28923621
[TBL] [Abstract][Full Text] [Related]
26. The Activity of Fosfomycin Against Extended-Spectrum Beta-Lactamase-Producing Isolates of Enterobacteriaceae Recovered from Urinary Tract Infections: A Single-Center Study Over a Period of 12 Years.
Aris P; Boroumand MA; Rahbar M; Douraghi M
Microb Drug Resist; 2018 Jun; 24(5):607-612. PubMed ID: 29064348
[TBL] [Abstract][Full Text] [Related]
27. Extended-spectrum beta-lactamase-producing Enterobacteriaceae (ESBL-PE) infections: are carbapenem alternatives achievable in daily practice?
Pilmis B; Delory T; Groh M; Weiss E; Emirian A; Lecuyer H; Lesprit P; Zahar JR
Int J Infect Dis; 2015 Oct; 39():62-7. PubMed ID: 26327124
[TBL] [Abstract][Full Text] [Related]
28. Comparison of fosfomycin to ertapenem for outpatient or step-down therapy of extended-spectrum β-lactamase urinary tract infections.
Veve MP; Wagner JL; Kenney RM; Grunwald JL; Davis SL
Int J Antimicrob Agents; 2016 Jul; 48(1):56-60. PubMed ID: 27234673
[TBL] [Abstract][Full Text] [Related]
29. Efficacy of non-carbapenem antibiotics for pediatric patients with first febrile urinary tract infection due to extended-spectrum beta-lactamase-producing Escherichia coli.
Abe Y; Inan-Erdogan I; Fukuchi K; Wakabayashi H; Ogawa Y; Hibino S; Sakurai S; Matsuhashi K; Watanabe Y; Hashimoto K; Ugajin K; Itabashi K
J Infect Chemother; 2017 Aug; 23(8):517-522. PubMed ID: 28528936
[TBL] [Abstract][Full Text] [Related]
30. Activity of beta-lactam beta-lactamase inhibitor combinations against extended spectrum Beta-lactamase producing Enterobacteriaceae in urinary isolates.
Afridi FI; Farooqi BJ
J Coll Physicians Surg Pak; 2012 Jun; 22(6):358-62. PubMed ID: 22630093
[TBL] [Abstract][Full Text] [Related]
31. Inappropriate empirical antibiotic therapy does not adversely affect the clinical outcomes of patients with acute pyelonephritis caused by extended-spectrum β-lactamase-producing Enterobacteriales.
Kim SH; Oh S; Huh K; Cho SY; Kang CI; Chung DR; Peck KR
Eur J Clin Microbiol Infect Dis; 2019 May; 38(5):937-944. PubMed ID: 30868326
[TBL] [Abstract][Full Text] [Related]
32. Oral treatment options for patients with urinary tract infections caused by extended spectrum βeta-lactamase (ESBL) producing Enterobacteriaceae.
Raja NS
J Infect Public Health; 2019; 12(6):843-846. PubMed ID: 31176606
[TBL] [Abstract][Full Text] [Related]
33. A clinical prediction tool for extended-spectrum β-lactamase-producing Enterobacteriaceae urinary tract infection.
Liu H; Qiu S; Chen M; Lyu J; Yu G; Xue L
BMC Infect Dis; 2022 Jan; 22(1):50. PubMed ID: 35027010
[TBL] [Abstract][Full Text] [Related]
34. Community-acquired febrile urinary tract infection caused by extended-spectrum beta-lactamase-producing bacteria in hospitalised infants.
Hernández Marco R; Guillén Olmos E; Bretón-Martínez JR; Giner Pérez L; Casado Sánchez B; Fujkova J; Salamanca Campos M; Nogueira Coito JM
Enferm Infecc Microbiol Clin; 2017 May; 35(5):287-292. PubMed ID: 26976379
[TBL] [Abstract][Full Text] [Related]
35. Alternatives to carbapenems for infections caused by ESBL-producing Enterobacteriaceae.
Pilmis B; Parize P; Zahar JR; Lortholary O
Eur J Clin Microbiol Infect Dis; 2014 Aug; 33(8):1263-5. PubMed ID: 24691683
[No Abstract] [Full Text] [Related]
36. Outcome of urinary tract infections caused by extended spectrum β-lactamase-producing Enterobacteriaceae in children.
Tratselas A; Iosifidis E; Ioannidou M; Saoulidis S; Kollios K; Antachopoulos C; Sofianou D; Roilides EJ
Pediatr Infect Dis J; 2011 Aug; 30(8):707-10. PubMed ID: 21248655
[TBL] [Abstract][Full Text] [Related]
37. Cefoxitin: An alternative to carbapenems in urinary tract infections due to extended-spectrum beta-lactamase-producing Enterobacteriaceae.
Mambie A; Vuotto F; Poitrenaud D; Weyrich P; Cannesson O; Dessein R; Faure K; Guery B; Galpérine T
Med Mal Infect; 2016 Jun; 46(4):215-9. PubMed ID: 27210283
[TBL] [Abstract][Full Text] [Related]
38. Childhood urinary tract infection caused by extended-spectrum β-lactamase-producing bacteria: Risk factors and empiric therapy.
Uyar Aksu N; Ekinci Z; Dündar D; Baydemir C
Pediatr Int; 2017 Feb; 59(2):176-180. PubMed ID: 27501161
[TBL] [Abstract][Full Text] [Related]
39. Urinary tract infections caused by ESBL-producing Enterobacteriaceae in renal transplant recipients: A systematic review and meta-analysis.
Alevizakos M; Nasioudis D; Mylonakis E
Transpl Infect Dis; 2017 Dec; 19(6):. PubMed ID: 28803446
[TBL] [Abstract][Full Text] [Related]
40. Management of infections caused by extended-spectrum β-lactamase-producing Enterobacteriaceae: current evidence and future prospects.
Sheu CC; Lin SY; Chang YT; Lee CY; Chen YH; Hsueh PR
Expert Rev Anti Infect Ther; 2018 Mar; 16(3):205-218. PubMed ID: 29402125
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]